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Background: Large breast size is associated with increased risk of late adverse effects after surgery and
radiotherapy for early breast cancer. It is hypothesised that effects of radiotherapy on adipose tissue are
responsible for some of the effects seen. In this study, the association of breast composition with late
effects was investigated along with other breast features such as ﬁbroglandular tissue distribution,
seroma and scar.
Methods: The patient dataset comprised of 18 cases with changes in breast appearance at 2 years follow-
up post-radiotherapy and 36 controls with no changes, from patients entered into the FAST-Pilot and UK
FAST trials at The Royal Marsden. Breast composition, ﬁbroglandular tissue distribution, seroma and scar
were assessed on planning CT scan images and compared using univariate analysis. The association of all
features with late-adverse effect was tested using logistic regression (adjusting for confounding factors)
and matched analysis was performed using conditional logistic regression.
Results: In univariate analyses, no statistically signiﬁcant differences were found between cases and
controls in terms of breast features studied. A statistically signiﬁcant association (p < 0.05) between
amount of seroma and change in photographic breast appearance was found in unmatched and matched
logistic regression analyses with odds ratio (95% CI) of 3.44 (1.28e9.21) and 2.57 (1.05e6.25),
respectively.
Conclusions: A signiﬁcant association was found between seroma and late-adverse effects after radio-
therapy although no signiﬁcant associations were noted with breast composition in this study. Therefore,
the cause for large breast size as a risk factor for late effects after surgery and optimally planned
radiotherapy remains unresolved.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
There is good evidence that large breast size is associated with
increased risk of late adverse effects after breast conserving surgery
and radiotherapy for early stage breast cancer [1e6]. Suboptimal
dosimetry in large-breasted women explains at least part of thisnd Imaging, The Royal Mars-
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Ltd. This is an open access article uassociation [4,5,7]. A randomised trial (N ¼ 306) comparing 3D and
2D radiation dosimetry showed that minimisation of unwanted
radiation dose inhomogeneity in the breast signiﬁcantly reduces
late adverse effects [8]. However, a study by Goldsmith et al. [3]
suggests that residual dose inhomogeneity in patients treated
with optimal dosimetry was insufﬁcient to explain the increased
risks of late adverse effects associated with large breast size.
Assessment of late adverse effects is made by clinicians, using
patient-reported outcomes and from patient photographs as
recorded in several breast radiotherapy trials [9e11]. The effects of
radiotherapy most easily noticed on photographs are changes innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of patient and treatment characteristics of cases and controls.
Cases
N ¼ 18
Controls
N ¼ 36
Age in years
Median (range) 66 (50e76) 65 (51e77)
Breast size,a n (%)
Small 6 (33%) 13 (36%)
Medium 8 (44%) 19 (53%)
Large 4 (22%) 4 (11%)
Surgical deﬁcit,a n (%)
Small 7 (39%) 23 (64%)
Medium 7 (39%) 7 (19%)
Large 4 (22%) 6 (17%)
Fractionation schedule, n (%)
Fast pilot trial e 30 Gy in 5 fractions over 3 weeks 5 (28%) 14 (39%)
Fast trial e 50 Gy in 25 fractions over 5 weeks 3 (17%) 8 (22%)
Fast trial e 30 Gy in 5 fractions over 5 weeks 6 (33%) 8 (22%)
Fast trial e 28.5 Gy in 5 fractions over 5 weeks 4 (22%) 6 (17%)
a Assessed from baseline photographs.
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There are suggestions that the shrinkagemay result from atrophy of
adipose cells in the breast. Preclinical studies suggest that radiation
induces a signiﬁcant reduction in both number and mean size of
adipocytes with consequent reduction in fat pad weight in mice
[12]. In large breasted women, the major component of the breast
by volume is adipose tissue [13,14]. This raises the possibility that a
higher proportion of adipose tissue in large breasted women may,
in some way, be responsible for some of the effects after radio-
therapy, particularly breast shrinkage.
The purpose of this study was to test the association of breast
composition and ﬁbroglandular tissue distribution with late
adverse effects after breast conservation surgery and radiotherapy.
This association, if found, could then be used for prediction of late
adverse effects of breast radiotherapy.
Methods
Patients
All patients from The Royal Marsden who had participated in
The Royal Marsden FAST Pilot and UK FAST Trial of radiotherapy
hypofractionation for treatment of early breast cancer
(ISRCTN62488883; CRUKE/04/015) [9,10] were identiﬁed. The FAST
Pilot study recruited 30 patients aged50 years with early invasive
breast cancer (tumour size < 3 cm, clear resection margins, nega-
tive axillary node status and no requirement for cytotoxic therapy).
They were prescribed 30 Gy in ﬁve fractions over 15 days to the
whole breast using tangential 6e10 MV X-ray beams and three-
dimensional dose compensation. The UK FAST Trial recruited 915
women with similar characteristics as above from 18 centres, 75 of
which were from The Royal Marsden. Patients were randomly
assigned to 50 Gy in 25 fractions versus 28.5 or 30 Gy in 5 once-
weekly fractions of 5.7 or 6.0 Gy, respectively, to the whole
breast. Both trials collected standardised pre-radiotherapy baseline
photographs of the breasts followed by repeat photographs at 2
years post-radiotherapy, along with annual clinical assessments.
Change in breast appearance (size and shape) were scored by three
observers on a 3-point scale (none, mild or marked change) from
the serial photographs at 2 years post-radiotherapy compared with
pre-radiotherapy baseline photographs [11].
Inclusion criteria for this study were, treatment at The Royal
Marsden, availability of CT planning scan images and a baseline and
2-year photographic assessment of change in breast appearance. All
eligible cases with mild or marked change in photographic breast
appearance were matched on fractionation schedule, breast size
and surgical deﬁcit (both scored as small/medium/large from
baseline photographs) to controls deﬁned as having no change in
photographic breast appearance at 2 years (Table 1). Where there
was more than one possible matched control per case, all of these
controls were selected for inclusion in the study. Other known
confounding factors such as chemotherapy, lymphatic radiotherapy
and radiotherapy boost were exclusion criteria for the FAST Pilot
and FAST trials.
Breast outlining
The CT data consisted of 3 mm axial slices (GE HiSpeed XQ/I (GE
Healthcare Ltd, Buckinghamshire, UK)). On each slice whole breast
was delineated by a single clinician (MB). The Hounsﬁeld units of
scar and seroma are similar to ﬁbroglandular tissue and therefore
these tissues are not easily differentiated using segmentation
methods [15]. The contralateral breast was used for the analysis of
breast composition and tissue distribution, in order to avoid the
effects of post-surgical seroma and scar on breast tissuesegmentation. The contralateral whole breast was outlined using
anatomical landmarks on planning CT scans for the treated breast
as described by Kirby et al. [16].
In some cases a portion of the breast was not contained in the
ﬁeld of view of the CT scanner (see Fig. 1b). These patients were
excluded, with some exceptions:
1. In 5 patients for whom only the skin was marginally not con-
tained in the ﬁeld of view, the anterior/surface margin was
brought right up to the visible edge.
2. In 2 patients for which a signiﬁcant proportion of the contra-
lateral breast was missing but the treated breast had a well-
deﬁned seroma, the treated breast and seroma was outlined
with the seroma excluded for the breast analysis (Fig. 1b).
Seroma was delineated using previously published guidelines
[17]. Examples of whole breast contours marked on a single CT slice
are shown in Fig. 1.Breast tissue automatic segmentation
The whole breast as deﬁned by the clinician on CT scans (see
Fig. 1) was segmented into adipose and ﬁbroglandular tissue using
an automated segmentation method. Our previous study [15],
showed that the fuzzy c-means clustering method with three
classes (adipose, ﬁbroglandular, and background) (FCM3) gave the
most accurate breast tissue segmentation when validated against
expert segmentation. FCM3 was used to ﬁnd the volume of adipose
tissue and percentage breast composition (BC) was calculated for all
patient datasets using the following equation:
BC ¼ 100*Vadi=Vtot
where, Vadi and Vtot are the volume of adipose tissue and whole
breast respectively.Clinician assessment of breast composition, ﬁbroglandular tissue
distribution, seroma and scar
Planning CT scan images were assessed by clinicians blind to
patients' case/control status. Breast composition and ﬁbroglandular
tissue distribution were also ranked by 3 clinicians (AK, MB and
NS), and seroma and scar were scored by a single clinician (MB)
using the following methods:
Fig. 1. Sample mid-breast CT images with whole breast contour marked: a. Contralateral breast; b. Treated breast with seroma outlined for exclusion in breast analysis, as the
contralateral breast proﬁle was not fully contained within the ﬁeld of view (shown by arrow).
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tissue was assessed for the whole breast and given one of the
following ranks: 1) <25%, 2) 25e50%, 3) 50e75% and 4) >75% of
adipose tissue.
Fibroglandular tissue distribution: Our previous study [15]
showed that ﬁbroglandular tissue distribution affects the accu-
racy of breast tissue segmentation. This was studied further [18]
and texture features were evaluated to identify the tissue distri-
bution. Four representative ranks (on scale of 1e4, where 1 is the
most sparse, i.e. very thin strands of ﬁbroglandular tissue) were
chosen based on 24 planning CT images from our previous studies
[15], see Fig. 2. The distribution of ﬁbroglandular tissue was ranked
by the clinicians using the contralateral breast, where possible, in
order to avoid the effects of seroma and scar tissue which have
Hounsﬁeld units similar to ﬁbroglandular tissue. Where the
contralateral breast was not fully containedwithin the ﬁeld of view,
the ipsilateral breast distribution was also considered for ranking.
The whole breast was assessed and ranked. The images were
viewed using the abdomen CT window setting (grey-level value
range 294e2650).
Assessment of seroma and scar tissue: The amount of seroma and
scar tissue in the treated breast at the time of radiotherapy plan-
ning were scored by the clinicians according to the following
criteria. Seroma score: 1 ¼ no seroma, 2 ¼ some seroma, 3 ¼ large
seroma and scar score: 1 ¼ no scar, 2 ¼ some scar, 3 ¼ large scar.Statistical methods
Since the number of available matching cases and controls was
small, the data were initially analysed using univariate analyses to
compare the cases and controls in terms of clinician-ranked and
algorithm-derived scores of breast density, amount of scar/seroma
ﬂuid, and distribution of ﬁbroglandular tissue. BC as measured by
auto-segmentation was compared between cases and controls us-
ing the t-test. Expert ranked breast composition and ﬁbroglandular
tissue distribution, and expert scored seroma and scar tissue were
compared between cases and controls using Fisher's exact test. In
some categories (rank/score) there were very small numbers (<3)
of patients and therefore for statistical testing categories were
combined. For breast composition, ranks 1 and 2, and ranks 3 and 4
were combined to form two categories: breast with 50% adipose
tissue and breast with >50% adipose tissue. For ﬁbroglandular tis-
sue distribution, ranks 1 and 2, and ranks 3 and 4 were combined to
form sparse and non-sparse breast groups. For seroma and scar,
scores 2 and 3 (some and large seroma/scar) were combined and
compared with score 1 (no seroma/scar). Following univariate
analysis, all the features were tested using logistic regression to
compare cases and controls, adjusting for fractionation schedule,breast size and surgical deﬁcit. Finally a matched analysis was
performed using conditional logistic regression. The primary
analysis was unmatched in order to maximise the sample size, as
some of the matched sets included more than one case and control.
The Wald test was used to assess statistical signiﬁcance in the
regression models [19].Results
In total therewere 18 cases withmild (n¼ 16) or marked change
(n ¼ 2) in photographic breast appearance at 2 years eligible for
inclusion into the study. Thirty-three matched controls were
selected, with at least one matched control per case (median
number of controls per case ¼ 1); there were 14 matched sets
altogether, ranging in size from 1 casewith 1 control to 3 cases with
4 controls. In addition, three unmatched controls were included in
the dataset in order to increase the sample size. The analysis was
based on these 54 patients who had evaluable planning CT images.
Table 1 summarises the patient and treatment characteristics of the
study sample.Univariate analysis
Table 2 summarises the results from univariate analysis for the
association of breast composition, ﬁbroglandular tissue distribu-
tion, seroma, and scar with change in photographic breast
appearance at 2 years. No signiﬁcant differences were found be-
tween cases and controls in terms of breast composition, tissue
distribution and scar. There was some evidence of higher seroma
scores in the cases (78% with some or large seroma compared with
47% of controls, although this was only of borderline statistical
signiﬁcance (p ¼ 0.07)).Logistic regression
Results from the logistic regression analysis and matched
analysis using conditional logistic regression are given in Table 3.
Logistic regression analysis suggested that after adjusting for frac-
tionation schedule, breast size and surgical deﬁcit, there was a
statistically signiﬁcant association between amount of seroma and
change in photographic breast appearance (odds ratio 3.44, 95% CI
1.28e9.21, p ¼ 0.01). Breast composition, breast tissue distribution
and scar were not signiﬁcantly associated with the measure of late
effects. The signiﬁcant association between amount of seroma and
change in photographic breast appearance was also evident in the
matched analysis (odds ratio 2.57, 95% CI 1.05e6.25, p ¼ 0.04).
Fig. 2. Sample mid-breast CT images for various distribution of ﬁbroglandular tissue in the breast based on expert ranking: a. No or sparse ﬁbroglandular distribution (rank ¼ 1); b.
Small clusters of ﬁbroglandular tissue (rank ¼ 2); c. Large cluster of ﬁbroglandular tissue (rank ¼ 3); d. Mainly ﬁbroglandular tissue (rank ¼ 4).
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A number of studies have shown that large breast size is asso-
ciated with an increased risk of late adverse effects [1e7]. This
raises the possibility that the increased proportion of adipose tissue
in large breasted women is, in some way, more sensitive to the
effects of radiotherapy. We investigated the association of patient-
related (breast composition, and tissue distribution), and
treatment-related (seroma and scar) breast features with late
adverse effects after breast conservation surgery and radiotherapy.
Breast composition was evaluated by auto-segmentation method
and by clinicians ranking of planning CT scan images. Against our
expectation, the present analysis failed to conﬁrm that breastcomposition may explain the association between large breast size
and late adverse effects. Breast tissue distribution and the presence
of scar tissue were also not signiﬁcantly associated with late
adverse effects.
Accurate estimation of breast composition using tissue seg-
mentation algorithms is difﬁcult, even in case of 3D data such as
MRI (magnetic resonance imaging) or CT. Nie et al. [20] noted in
their study of breast MRI, a 3e6% variation in measurements of
ﬁbroglandular composition with body positioning. In our previous
study [15], unexpectedly large variations (>10%) between prone
and supine ﬁbroglandular composition measurements were found
for 7 of 24 patients. Furthermore clinician ranking of breast
composition is widely variable [21]. Another limitation of the
Table 2
Results from univariate analysis, testing the association of breast composition measured by the auto-segmentation method and clinicians rank, ﬁbroglandular tissue distri-
bution, seroma, and scar with the late adverse effects.
Feature Cases Controls p-Value
Breast composition Auto-segmentation mean BC (SD) 83.2 (15.3) 81.1 (21.8) 0.72a
Ranks 1 & 2, n (%) 3 (16.7%) 9 (25.0%) 0.73b
Ranks 3 & 4, n (%) 15 (83.3%) 27 (75.0%)
Fibroglandular tissue distribution Sparse (ranks 1 & 2), n (%) 9 (50.0%) 14 (38.9%) 0.63b
Non-sparse (ranks 3 & 4), n (%) 9 (50.0%) 22 (61.1%)
Seroma None (score 1), n (%) 4 (22.2%) 19 (52.8%) 0.07b
Some/large (scores 2 & 3), n (%) 14 (77.8%) 17 (47.2%)
Scar None (score 1), n (%) 6 (33.3%) 14 (38.9%) 0.92b
Some/large (scores 2 & 3), n (%) 12 (66.7%) 22 (61.1%)
a t-Test.
b Fisher's exact test.
Table 3
Results of unmatched and matched logistic regression analyses testing associations between breast features and late adverse effects.
ORa (95% CI)
p-value
ORb (95% CI)
p-value
Automated segmentation: breast composition 0.98 (0.94e1.03) 0.99 (0.93e1.05)
p ¼ 0.46 p ¼ 0.70
Clinician ranked: breast composition 1.50 (0.53e4.24) 2.03 (0.71e5.79)
p ¼ 0.45 p ¼ 0.19
Breast tissue distribution 0.90 (0.32e2.58) 0.57 (0.20e1.62)
p ¼ 0.85 p ¼ 0.29
Seroma 3.44 (1.28e9.21) 2.57 (1.05e6.25)
p ¼ 0.01 p ¼ 0.04
Scar 1.19 (0.33e4.24) 1.07 (0.35e3.22)
p ¼ 0.79 p ¼ 0.91
a Odds ratio from logistic regression adjusted for fractionation schedule, breast size, and surgical deﬁcit.
b Odds ratio from matched analysis using conditional logistic regression.
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the breast composition and tissue distribution is the same when
measured in contralateral and ipsilateral breast; this might not
always be true. Alonzo-Proulx et al. [22] in their study, using digital
mammograms of 15,351 individual women, found that the average
relative difference in right and left breast density (percentage of
ﬁbroglandular tissue in the breast) was 21%.
However, our results showed that a larger seroma is signiﬁ-
cantly associated with late effects, measured using change in
photographic breast appearance. The odds ratio of 2.57 obtained
from thematched analysis suggests that for increase in the category
of seroma (none to some or very large), the risk of being a case (i.e.
of developing late effects) increases by an estimated factor of
around 2.5, although the 95% conﬁdence interval was wide
(1.05e6.25). Previously Mukesh et al. have shown that the presence
of seroma is an independent risk factor for late normal tissue
toxicity (whole breast and tumour bed induration) at 2 and 5 years
[23]. Their results suggested that seroma is associated with overall
cosmesis, taking into account both surgical and radiotherapy
changes using serial photographs. In the current study, cases and
controls were matched for breast size to remove the inﬂuence of
breast size on the outcomes.
Both seroma and scar could be deﬁnedmore objectively through
quantiﬁcation of their respective sizes rather than visual assess-
ment as performed in this study. However, these volumes are small
and likely to have substantial variability in outlines with intra and
inter-expert variations. Seroma and scar are often used as a sur-
rogate for tumour bed in breast radiotherapy, where applicable. For
tumour bed, substantial outline variability has been noted in a
number of studies, including van Mourik et al. [24] who found
mean conformity index to be 0.44 (range: 0.10e0.83). It is likely
that seroma and scar will have at least similar uncertainty in out-
lining as tumour bed. Therefore, in the absence of accuratemeasurement of seroma and scar sizes, qualitative visual assess-
ments for these were used.
One limitation of this study is the small sample size, and in
particular the number of eligible cases. In order to detect an odds
ratio of 2 for a risk factor with 50% prevalence in the controls, we
would need 200 cases and 200 controls, assuming a 2-sided sig-
niﬁcance of 0.05 and 80% power. It would therefore be interesting
to investigate a patient cohort with a larger number of cases with
the analysis approach developed here. It should be noted that the
analysis presented in this study is based onphotographic scores at 2
years follow-up and it is certain that not all patients have expressed
their ﬁnal level of toxicity. Therefore, investigation of late adverse
effects at 5 years after the completion of radiotherapy is warranted.
Furthermore, most of the cases (16 out of 18) had mild change in
photographic breast appearance which may also have contributed
to the lack of association with breast composition. The current In-
tensity Modulated Partial Organ Radiotherapy (IMPORT) High trial
[25] is aimed at delivering an escalated dose to the tumour bed in
the test groups for women at a higher than average risk of recur-
rence. This randomised trial of around 2500 patients might provide
a good dataset for studying the association of breast composition
with late adverse effects. Investigation of these large numbers of
patients will need to be automated as much as possible through the
validated methods in literature [15,18].Conclusions
In conclusion, this study found that seroma is signiﬁcantly
associated with late adverse effects of radiation as recorded by
change in breast appearance on photographs at 2 years. Our pre-
liminary results suggest that breast composition and tissue distri-
bution, and a larger scar are not associatedwith late adverse effects.
P. Juneja et al. / The Breast 26 (2016) 25e3030However, this needs to be interpreted with caution given the small
data set.
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